Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

343
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
343
Criteria for Causality: Bradford Hill Criteria - II01:28

Criteria for Causality: Bradford Hill Criteria - II

1.1K
The Bradford Hill criteria serve as guidelines for establishing causative links in epidemiological research. Beyond Strength, Consistency, Specificity, and Temporality, key criteria also include Biological Gradient, Plausibility, Coherence, Experiment, and Analogy. These principles assist scientists in assessing the likelihood of causation in complex biological contexts. Below is a summary of these concepts:
1.1K
Causality in Epidemiology01:21

Causality in Epidemiology

1.5K
Causality or causation is a fundamental concept in epidemiology, vital for understanding the relationships between various factors and health outcomes. Despite its importance, there's no single, universally accepted definition of causality within the discipline. Drawing from a systematic review, causality in epidemiology encompasses several definitions, including production, necessary and sufficient, sufficient-component, counterfactual, and probabilistic models. Each has its strengths and...
1.5K
Confounding in Epidemiological Studies01:27

Confounding in Epidemiological Studies

556
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
556
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

388
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
388
Criteria for Causality: Bradford Hill Criteria - I01:30

Criteria for Causality: Bradford Hill Criteria - I

999
The Bradford Hill criteria are a group of principles that provide a framework to determine a causal relationship between a specific factor and a disease. There are nine criteria that are pivotal in assessing causality in epidemiological studies. Here's a closer look at Strength, Consistency, Specificity, and Temporality criteria with definitions and examples:
999

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Learning Covariate Relations in Disease Progression Models Using Symbolic Neural Networks.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer.

Clinical pharmacology and therapeutics·2025
Same author

Predictors of Ability to Work in Multiple Sclerosis.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Response to "Enhance Multistate Models With Clinically Meaningful Graphs".

CPT: pharmacometrics & systems pharmacology·2025
Same author

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders.

CPT: pharmacometrics & systems pharmacology·2025
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.5K

在暴露-反应分析中解决因果关系和同质性假设.

Mats O Karlsson1, Divya Brundavanam1

  • 1Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Clinical pharmacology and therapeutics
|November 25, 2025
PubMed
概括
此摘要是机器生成的。

新的仪器变量 (IV) 模型通过评估因果关系和同质性来改善药理动力学分析 (PKPD). 分区效应 (PE) 模型准确地估计了各种混场景中的药物效应,与标准PKPD模型不同.

更多相关视频

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
11:40

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC

Published on: January 30, 2018

13.6K

相关实验视频

Last Updated: Jan 10, 2026

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
11:40

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC

Published on: January 30, 2018

13.6K

科学领域:

  • 制药指标 (Pharmacometrics) 是一个指标.
  • 生物统计学 生物统计学
  • 药物开发 药物开发

背景情况:

  • 暴露-反应 (PKPD) 分析对于药物开发决策至关重要.
  • 当前的PKPD模型往往缺乏对因果关系和同质性的评估,这可能导致偏见的结果.
  • 仪表变量 (IV) 分析提供了一种方法来确定因果关系.

研究的目的:

  • 适应和评估IV模型 (预测器替代和控制功能) 用于重复测量分析.
  • 将这些IV模型与标准PKPD模型和新型分区效应 (PE) 模型进行比较.
  • 在各种混杂情景下评估模型性能,包括共享潜变量,未测量的活性代谢物和逆向因果关系.

主要方法:

  • 调整预测器替代 (PS) 和控制函数 (CF) IV模型的重复测量数据.
  • 与PKPD模型 (具有和没有PK-PD随机效应相关性) 和分区效应 (PE) 模型进行比较.
  • 模拟六种情景:没有混,三种类型的混,未测量的活性代谢物和反向因果关系.

主要成果:

  • 在大多数模拟场景中,标准PKPD模型产生了偏差的参数估计和不适当的剂量建议.
  • 在大多数场景中,PS和CF模型提供了足够的估计.
  • 新的PE模型始终在所有模拟场景中提供足够的估计,包括复杂的混情况.

结论:

  • PE模型为因果暴露-反应建模提供了强大的方法,在混下优于传统的PKPD方法.
  • PE模型支持基于度或反应的剂量足够个性化.
  • 适应的IV方法,特别是PE模型,对于可靠的药物开发决策,无论是单一的还是重复的措施,都是有价值的.